SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-23-009024
Filing Date
2023-07-28
Accepted
2023-07-28 17:01:12
Documents
14
Period of Report
2023-07-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_072823.htm   iXBRL 8-K 41108
2 PRESS RELEASE ISSUED BY THE COMPANY DATED JULY 28, 2023 ex99-1.htm EX-99.1 15889
6 GRAPHIC admp-01.jpg GRAPHIC 14170
  Complete submission text file 0001387131-23-009024.txt   253109

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20230728.xsd EX-101.SCH 2998
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20230728_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20230728_pre.xml EX-101.PRE 22385
8 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_072823_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 231123899
SIC: 2834 Pharmaceutical Preparations